These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 28011497

  • 1. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
    Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, Uchikado Y, Arigami T, Uenosono Y, Mori S, Ueno S, Shinchi H, Natsugoe S.
    Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
    [Abstract] [Full Text] [Related]

  • 2. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
    Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J.
    BMC Cancer; 2012 Dec 20; 12():609. PubMed ID: 23256481
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T.
    Cancer Chemother Pharmacol; 2017 Jul 20; 80(1):195-202. PubMed ID: 28597040
    [Abstract] [Full Text] [Related]

  • 4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y, Sun J, Jiang Z, Zhang L, Liu G.
    J Chemother; 2015 Aug 20; 27(4):227-34. PubMed ID: 25790948
    [Abstract] [Full Text] [Related]

  • 5. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.
    Cancer; 2013 Jan 15; 119(2):277-84. PubMed ID: 22778019
    [Abstract] [Full Text] [Related]

  • 6. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Huang WK, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, Yang TS, Chen JS.
    Anticancer Res; 2014 Nov 15; 34(11):6755-61. PubMed ID: 25368287
    [Abstract] [Full Text] [Related]

  • 7. Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
    Shinoto M, Nakamura K, Shioyama Y, Sasaki T, Nishie A, Asayama Y, Ohga S, Yoshitake T, Terashima K, Asai K, Matsumoto K, Honda H.
    Anticancer Res; 2016 Apr 15; 36(4):1879-84. PubMed ID: 27069174
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, Mitsunaga S, Shimizu S.
    Cancer Chemother Pharmacol; 2010 Aug 15; 66(3):527-34. PubMed ID: 19967537
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
    Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S, Hara K, Yazumi S, Shimizu Y, Yamao K.
    Eur J Cancer; 2016 Feb 15; 54():96-103. PubMed ID: 26741729
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
    Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H, Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG).
    Jpn J Clin Oncol; 2021 Feb 08; 51(2):235-243. PubMed ID: 33164066
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
    Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L, Liu T, Xu B, Feng Y, Wang Y, Lou W, Zhou Y.
    Jpn J Clin Oncol; 2018 Jun 01; 48(6):535-541. PubMed ID: 29718363
    [Abstract] [Full Text] [Related]

  • 12. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F.
    World J Gastroenterol; 2014 Oct 14; 20(38):13987-92. PubMed ID: 25320537
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
    Yang PC, Huang KW, Pua U, Kim MD, Li SP, Li XY, Liang PC.
    Eur J Surg Oncol; 2020 May 14; 46(5):811-817. PubMed ID: 31839436
    [Abstract] [Full Text] [Related]

  • 14. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma.
    Yang SH, Shao YY, Lin CC, Kuo SH, Cheng AL, Yeh KH.
    Anticancer Res; 2018 Aug 14; 38(8):4805-4812. PubMed ID: 30061252
    [Abstract] [Full Text] [Related]

  • 15. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
    Tomihara H, Eguchi H, Yamada D, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y.
    Surg Today; 2017 Feb 14; 47(2):218-226. PubMed ID: 27586014
    [Abstract] [Full Text] [Related]

  • 16. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
    Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I.
    Oncotarget; 2016 Mar 15; 7(11):12672-81. PubMed ID: 26862857
    [Abstract] [Full Text] [Related]

  • 17. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
    Sasajima J, Tanno S, Koizumi K, Nakano Y, Habiro A, Chiba A, Fujii T, Sugiyama Y, Nakamura K, Nishikawa T, Mizukami Y, Okumura T, Kohgo Y.
    Gan To Kagaku Ryoho; 2009 Oct 15; 36(10):1657-61. PubMed ID: 19838023
    [Abstract] [Full Text] [Related]

  • 18. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR.
    Int J Radiat Oncol Biol Phys; 2014 Jun 01; 89(2):284-91. PubMed ID: 24726286
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, Ozkan L, Evrensel T, Kaya E, Manavoglu O.
    Tumori; 2006 Jun 01; 92(6):481-6. PubMed ID: 17260487
    [Abstract] [Full Text] [Related]

  • 20. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Umemura A, Nitta H, Sasaki A, Takahara T, Hasegawa Y, Wakabayashi G.
    Hepatogastroenterology; 2014 May 01; 61(131):814-20. PubMed ID: 26176079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.